-
-
-
-
-
-
-
William Blair on Neurogene (NGNE): dosing update further de-risks NGN-401 profile
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Neurogene (NGNE)
-
-
-
-
-
-
-
Neurogene (NGNE) Announces Registrational Trial Design for Embolden Study of NGN-401 Gene Therapy
-
-
-
-
-
-
-
Baird Downgrades Neurogene (NGNE) to Neutral
-
-
-
-
-
-
-
Neurogene (NGNE) PT Lowered to $45 at BMO Capital
-
-
-
-
-
-
-
Neurogene (NGNE) PT Raised to $55 at H.C. Wainwright
-
-
-
-
-
-
-
Neurogene (NGNE) Receives RMAT Designation for NGN-401
-
413,645 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

